McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns. - Barron's
1. McKesson's stock has jumped 45% since October 2023 due to strong demand. 2. Morgan Stanley raised MCK's price target to $745, signaling confidence in growth. 3. McKesson's earnings expected to climb double-digits, outperforming broader market. 4. The company remains insulated from pricing pressure despite thin profit margins. 5. Recent acquisition enhances McKesson’s specialty services and market position.